New hope for Tough-to-Treat lung cancer: Real-World data on targeted drug
NCT ID NCT07198620
Summary
This study looks back at the real-world use of the drug IBI351 in 600 Chinese patients with a specific, hard-to-treat form of advanced lung cancer (KRAS G12C mutation). The main goal is to see how well the drug worked in everyday clinical practice and how safe it was for patients. Researchers will analyze patient records to measure tumor shrinkage, how long the treatment worked, and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,
Guangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.